RESUMEN
AIMS: To compare effects of heparin and hirudin on biochemical markers of coagulation. METHODS AND RESULTS: Patients (n=395) with unstable angina or myocardial infarction without ST elevation were randomized to a 72-h infusion of one of three regimens: unfractionated heparin (bolus of 5000 IU followed by an infusion of 1200 IU. h(-1)), low-dose hirudin (HBW 023; 0.2 mg. kg(-1)bolus followed by 0.10 mg. kg(-1). h(-1)) or medium-dose hirudin (0.4 mg. kg(-1)bolus followed by 0.15 mg. kg(-1). h(-1)). Infusions were adjusted to maintain an activated partial thromboplastin time of between 60-100 s. Activated partial thromboplastin time, prothrombin fragment 1.2 (F1.2), thrombin antithrombin III complex and D-dimer were measured before, during and after the infusion. Median activated partial thromboplastin time was similar in the two groups early on, but was significantly lower in the heparin group than in the combined hirudin group 48 h after starting the infusion (53 s and 75 s, respectively;P<0.001), and 6 h after stopping (31 s and 46 s, respectively;P<0.001). Median F1.2 levels were not significantly different between the groups during the infusion. Median thrombin antithrombin III levels in the heparin and hirudin groups were 2.8 microg. l(-1)and 2.3 microg. l(-1), respectively, at 6 h (P<0.001), and 3.0 microg. l(-1)and 2.3 microg. l(-1), respectively, at 48 h (P<0.001). Median D-dimer levels were 320 ng. ml(-1)and 260 ng. ml(-1)48 h after starting the infusion in the heparin and hirudin groups, respectively (P<0.001), and 415 ng. ml(-1)and 280 ng. ml(-1), respectively (P<0.001) 6 h after stopping. D-dimer levels were significantly elevated above baseline values in both groups 24-48 h after stopping the infusions. CONCLUSIONS: The greater reduction of thrombin antithrombin III and D-dimer during the hirudin infusion supports the hypothesis that hirudin is a more potent antithrombin agent than heparin. Increased D-dimer levels after stopping heparin or hirudin suggest that there is an ongoing pro-coagulant state. These results point to the greater efficacy of hirudin in preventing early clinical events (death, myocardial infarction and refractory ischaemia) compared with heparin that have been observed in large randomized trials. Persistent activation of coagulation afterstopping infusions in our study suggests that a longer course of antithrombotic treatment may be needed to pacify the thrombus.
Asunto(s)
Angina Inestable/prevención & control , Anticoagulantes/administración & dosificación , Antitrombinas/administración & dosificación , Fibrinolíticos/administración & dosificación , Heparina/administración & dosificación , Hirudinas/administración & dosificación , Infarto del Miocardio/prevención & control , Antitrombina III/análisis , Biomarcadores/sangre , Coagulación Sanguínea , Canadá , Esquema de Medicación , Electrocardiografía , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Fragmentos de Péptidos/metabolismo , Protrombina/metabolismo , Proteínas Recombinantes/administración & dosificaciónRESUMEN
Hypertrophic obstructive cardiomyopathy is a disease of the myocardium that can be assessed echocardiographic and transcutaneous Doppler ultrasound techniques. Four patients are presented with various patterns of the disease, and the frequently familial incidence is illustrated. The importance of ultrasonic evidence for asymmetric septal hypertrophy in all stages is emphasized and evidence of reduced septal contractility demonstrated. Abnormalities of mitral valve motion, slow diastolic closure rate and systolic anterior movement of the anterior leaflet, are shown in the obstructive form of the disease. Also partial mid-systolic aortic valve closure and aortic cusp flutter are shown with outflow obstruction. The outflow tract gradient can be calculated from mitral valve to septum systolic distances. Transcutaneous Doppler ultrasound shows a normal aortic velocity pattern in nonobstructive disease while consistent abnormalities are present with severe resting obstruction. Isoprenaline can be used to alter the normal velocity pattern associated with a minimal resting gradient to an abnormal pattern indicating the development of significant obstruction.